Pharmacyclics, Johnson & Johnson Nab Breakthrough Designation for New Cancer Drug
Pharmacyclics (NASDAQ:PCYC) says its experimental drug for a pair of rare blood cancers received a new designation from US officials that potentially sets it up for a quick approval. The news sent Pharmacyclics shares higher Wednesday morning. Pharmacyclics and development partner Johnson & Johnson (NYSE:JNJ) won the classification “breakthrough therapy” by the Food and Drug Administration for the oral drug ibrutinib as a single treatment for two cancers. That means the FDA will accept early clinical evidence showing that the drug is a big improvement over existing treatments. Hopes for approval of the drug are already high. Shares of ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here